Lexaria Bioscience CORP. (LEXX) — 10-K Filings
All 10-K filings from Lexaria Bioscience CORP.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Lexaria Bioscience R&D Surges to $8.2M, Bolstering DehydraTECH Patents
— Nov 28, 2025 Risk: high
Lexaria Bioscience Corp. (LEXX) reported an R&D expense of $8.2 million in fiscal 2025, focusing on its patented DehydraTECH drug delivery technology. The compa -
Lexaria Bioscience Files 2024 10-K
— Nov 26, 2024 Risk: medium
Lexaria Bioscience Corp. filed its 10-K for the fiscal year ending August 31, 2024. The company, incorporated in Nevada, operates in the pharmaceutical preparat
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX